24/08/2021 (Agence Europe) – The pharmaceutical company Valneva hopes that the phase III trial of its Covid-19 vaccine candidate (VLA2001), which is currently underway, will demonstrate “an efficacy rate of more than 80%”. These comments, which were made on 24 August by the company’s managing director, Franck Grimaud, were reported by AFP. The press agency notes that such efficiency would be lower than that of the vaccines from Pfizer/BioNTech and Moderna (which is 95%), but higher...